SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 at 2:15pm EDT. To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary. About Rigel ( www.rigel.com) Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. Rigel has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. Contact: Raul RodriguezPhone: 650.624.1302Email: email@example.com Media Contact: Jessica DaitchPhone: 917.816.6712Email: firstname.lastname@example.orgView original content with multimedia: http://www.prnewswire.com/news-releases/rigel-to-present-at-cantor-fitzgerald-global-healthcare-conference-300521736.html SOURCE Rigel Pharmaceuticals, Inc.